Nucleic acid amplification method: ramification-extension amplification method (RAM)

• US 5,942,391 A
• Filed: 07/31/1996
• Issued: 08/24/1999
• Est. Priority Date: 06/22/1994
• Status: Expired due to Term

• Current Assignee: Mount Sinai School of Medicine (Sinai Health System)
• Original Assignee: Mount Sinai School of Medicine (Sinai Health System)
• Inventors: Hsuih, Terence C. H., Zhang, David Y., Brandwein, Margaret
• Primary Examiner(s): Jones, W. Gary
• Assistant Examiner(s): WHISENANT, ETHAN C
• Application Number:
  US08/690,494
• Time in Patent Office: 1,119 Days
• Field of Search: 435/5, 435/6, 435/91.2, 536/24.3, 536/32, 536/33
• US Class Current: 435/6.12
• CPC Class Codes: C12Q 1/6816 characterised by the detection means C12Q1/6804 takes precedence
• CPC Class Codes: C12Q 1/6834 Enzymatic or biochemical coupling of nucleic acids to a solid phase
• CPC Class Codes: C12Q 1/686 Polymerase chain reaction [PCR]
• CPC Class Codes: C12Q 1/6862 Ligase chain reaction [LCR]
• CPC Class Codes: C12Q 1/689 for bacteria
• CPC Class Codes: C12Q 2521/501 Ligase
• CPC Class Codes: C12Q 2523/101 Crosslinking agents, e.g. psoralen
• CPC Class Codes: C12Q 2525/161 incorporating target specific and non-target specific sites
• CPC Class Codes: C12Q 2525/185 incorporating bases where the precise position of the bases in the nucleic acid string is important
• CPC Class Codes: C12Q 2525/307 Circular oligonucleotides
• CPC Class Codes: C12Q 2533/107 Probe or oligonucleotide ligation
• CPC Class Codes: C12Q 2537/125 Sandwich assay format
• CPC Class Codes: C12Q 2563/131 the label being a member of a cognate binding pair, i.e. extends to antibodies, haptens, avidin
• CPC Class Codes: C12Q 2563/143 Magnetism, e.g. magnetic label
• CPC Class Codes: C12Q 2565/519 characterised by the capture moiety being a single stranded oligonucleotide
• CPC Class Codes: C12Q 2565/543 characterised by the use of two or more capture oligonucleotide primers in concert, e.g. bridge amplification
• CPC Class Codes: Y10T 436/143333 Saccharide [e.g., DNA, etc.]

Abstract

An improved method allowing for rapid sensitive and standardized detection of a target nucleic acid from a pathogenic microorganism or virus or normal or abnormal gene in a sample is provided. The method involves hybridizing a target nucleic acid to several non-overlapping oligonucleotide probes that hybridize to adjacent regions in the target nucleic acid, the probes being referred to capture/amplification probes and amplification probes, respectively, in the presence of paramagnetic beads coated with a ligand binding moiety. Through the binding of a ligand attached to one end of the capture/amplification probe and the specific hybridization of portions of the probes to adjacent sequences in the target nucleic acid, a complex comprising the target nucleic acid, the probes and the paramagnetic beads is formed. The probes may then ligated together to form a contiguous ligated amplification sequence bound to the beads, which complex may be denatured to remove the target nucleic acid and unligated probes. Alternatively, separate capture and amplification probes may be used which form continuous full-length or circular probes, and may be directly detected or amplified using a suitable amplification technique, e.g., PCR, RAM or HSAM for detection. The detection of the ligated amplification sequence, either directly or following amplification of the ligated amplification sequence, indicates the presence of the target nucleic acid in a sample. Methods for the detection of the ligated amplification sequence, including hybridization signal amplification method and ramification-extension amplification method, are also provided.

Claims

1. A method for detecting a target nucleic acid in a sample comprising:

(a) contacting said nucleic acid in said sample in a reaction vessel under conditions that allow nucleic acid hybridization between complementary sequences in nucleic acids with oligonucleotide probes in the presence of paramagnetic particles coated with a ligand binding moiety, said oligonucleotide probes comprising one or more capture/amplification probes, each having a 3'"'"' nucleotide sequence that is neither complementary nor hybridizable to a nucleotide sequence in the target nucleic acid, and a 5'"'"' nucleotide sequence that is complementary and hybridizable to a nucleotide sequence in the target nucleic acid, or a 5'"'"' nucleotide sequence that is neither complementary nor hybridizable to a nucleotide sequence in the target nucleic acid, and a 3'"'"' nucleotide sequence that is complementary and hybridizable to a nucleotide sequence in the target nucleic acid, each capture/amplification probe further having a ligand bound to the non-complementary sequence of the probe, wherein said ligand is capable of binding to and forming an affinity pair with said ligand binding moiety coated onto said paramagnetic particles;

said oligonucleotide probes further comprising a circularizable amplification probe having 3'"'"' and 5'"'"' regions that are complementary to adjacent but noncontiguous sequences in the target nucleic acid, said 3'"'"' and 5'"'"' regions separated by a linker region that is neither complementary nor hybridizable to a nucleotide sequence in the target nucleic acid, such that a complex is formed comprising the target nucleic acid, circularizable probe, capture/amplification probes and paramagnetic particles, wherein the capture/amplification probes are hybridized to the complementary nucleotide sequences in the target nucleic acid and are bound to the paramagnetic particles through the binding of the ligand on the capture/amplification probe to the ligand binding moiety on the paramagnetic particles, and the circularizable probe is bound on its 3'"'"' and 5'"'"' ends to adjacent but noncontiguous sequences in the target nucleic acid;

(b) separating the complex from unbound reactants and washing the complex;

(c) ligating the 3'"'"' and 5'"'"' ends of said circularizable probe with a ligating agent that joins nucleotide sequences such that a circular amplification probe is formed;

(d) amplifying said circular amplification probe by contacting said complex with a first extension primer that is complementary and hybridizable to a portion of the linker region of the circular amplification probe and a second extension primer that is substantially identical to a portion of the linker region of the circular amplification probe that does not overlap with the portion of the linker region to which the first extension primer is complementary, dNTPs, and a DNA polymerase having strand displacement activity, under conditions whereby the first extension primer is extended around the circle for multiple revolutions to form a single stranded DNA of repeating units complementary to the sequence of the circular probe, and multiple copies of the second extension primer hybridize to complementary regions of the single stranded DNA and are extended by the DNA polymerase to provide extension products, and whereby the extension products of the second extension primers displace downstream copies of the second extension primers and corresponding extension products of said downstream copies to provide displaced single strands to which multiple copies of said first extension primer bind and are extended by the DNA polymerase;

(e) allowing said amplification to proceed until multiple copies of double stranded amplified DNA of varying lengths are produced; and

(f) detecting said amplified DNA, wherein detection thereof indicates the presence of the target nucleic acid in the clinical sample.

5. The method of claim 1 wherein said second extension primer contains a promoter sequence for a DNA-dependent RNA polymerase, and step (d) further comprises the addition of a DNA-dependent RNA polymerase and rNTPs under conditions whereby an RNA copy of the single stranded DNA is made.

6. The method of claim 1 wherein said DNA polymerase is selected from the group consisting of (exo^-) Klenow fragment of DNA polymerase, Thermococcus litoralis (exo^-) DNA polymerase, and Thermus aquaticus DNA polymerase.

8. The method claim 5 wherein said DNA-dependent RNA polymerase is bacteriophage T3 RNA polymerase bacteriophage T7 RNA polymerase, or bacteriophage SP6 RNA polymerase.

9. The method of claim 1 which further comprises contacting said sample with an exonuclease after step (c) and before step (d).

10. The method of claim 1 wherein said target nucleic acid is specific for a pathogenic microorganism or virus.

11. The method of claim 1 wherein said target nucleic acid is a wild-type or mutant human gene.

12. The method of claim 1 wherein said target nucleic acid is an RNA or DNA molecule.

13. The method of claim 1 wherein said ligand is selected from the group consisting of biotin, antigens, haptens, antibodies, heavy metal derivatives, and polynucleotides including poly dG, polydT, polydC, polyda and polyU.

14. The method of claim 1 wherein said ligand binding moiety is selected from the group consisting of streptavidin, avidin, antibodies, antigens, thio groups and polynucleotides including poly dC, poly dA, poly dG, poly dT and poly U.

15. The method of claim 1 wherein said ligand is biotin and said ligand binding moiety is streptavidin.

16. The method of claim 1 wherein said ligating agent is an enzyme or chemical agent.

17. The method of claim 16 wherein said enzyme is a DNA or RNA ligase.

18. The method of claim 16 wherein said DNA ligase is T4 DNA ligase or Taq DNA ligase.

19. The method of claim 16 wherein said chemical agent is cyanogen bromide or a carbodiimide.

20. The method of claim 1 further comprising subjecting the paramagnetic particles to a magnetic field sufficient to prevent loss of the particles from the reaction vessel during the separating and washing steps.

21. The method of claim 1 wherein said target nucleic acid is selected from the group consisting of HIV-1 RNA, mycobacteria ribosomal RNA, HCV RNA, and EBV RNA.

22. The method of claim 21 wherein said ribosomal RNA is 16S rRNA selected from the group consisting of mycobacteria spp., M. tuberculosis, M. avium and M. intracellulaire.

2. A method for detecting a target nucleic acid in a sample comprising:

(a) contacting said nucleic acid in said sample in a reaction vessel under conditions that allow nucleic acid hybridization between complementary sequences in nucleic acids with oligonucleotide probes in the presence of paramagnetic particles coated with a ligand binding moiety, said oligonucleotide probes comprising one or more capture amplification probes, each having a 3'"'"' nucleotide sequence that is neither complementary nor hybridizable to a nucleotide sequence in the target nucleic acid, and a 5'"'"' nucleotide sequence that is complementary and hybridizable to a nucleotide sequence in the target nucleic acid, or a 5'"'"' nucleotide sequence that is neither complementary nor hybridizable to a nucleotide sequence in the target nucleic acid, and a 3'"'"' nucleotide sequence that is complementary and hybridizable to a nucleotide sequence in the target nucleic acid, each capture/amplification probe further having a ligand bound to the non-complementary sequence of the probe, wherein said ligand is capable of binding to and forming an affinity pair with said ligand binding moiety coated onto said paramagnetic particles;

said oligonucleotide probes further comprising a circularizable amplification probe having 3'"'"' and 5'"'"' regions that are complementary to adjacent but noncontiguous sequences in the target nucleic acid, said 3'"'"' and 5'"'"' regions separated by a linker region that is neither complementary nor hybridizable to a nucleotide sequence in the target nucleic acid, such that a complex is formed comprising the target nucleic acid, circularizable probe, capture/amplification probes and paramagnetic particles, wherein the capture/amplification probes are hybridized to the complementary nucleotide sequences in the target nucleic acid and are bound to the paramagnetic particles through the binding of the ligand on the capture/amplification probe to the ligand binding moiety on the paramagnetic particles, and the circularizable probe is bound on its 3'"'"' and 5'"'"' ends to adjacent but noncontiguous sequences in the target nucleic acid;

(b) separating the complex from unbound reactants and washing the complex;

(c) ligating the 3'"'"' and 5'"'"' ends of said circularizable probe with a ligating agent that joins nucleotide sequences such that a circular amplification probe is formed;

(d) amplifying said circular amplification probe by contacting said complex with an extension primer that is complementary and hybridizable to a portion of the linker region of the circular amplification probe, dNTPs, and a DNA polymerase having strand displacement activity, under conditions whereby said extension primer is extended around the circle for multiple revolutions to form a single stranded DNA of repeating units complementary to the sequence of the circular probe; and

(e) detecting said single stranded DNA, wherein detection thereof indicates the presence of the target nucleic acid in the clincal sample.

7. The method claim 2 wherein said DNA polymerase is selected from the group consisting of (exo^-) Klenow fragment of DNA polymerase, Thermococcus litoralis (exo^-) DNA polymerase, and Thermus apuaticus DNA polymerase.

3. A method for in situ detection of a target nucleic acid in a sample comprising the steps of:

(a) preparing a tissue sample from the histological specimen to be analyzed for the presence of the target nucleic acid;

(b) washing said tissue sample;

(c) adding a circularizable amplification probe having 3'"'"' and 5'"'"' regions that are complementary to adjacent but noncontiguous sequences in the target nucleic acid, said 3'"'"' and 5'"'"' regions separated by a linker region that is neither complementary nor hybridizable to a nucleotide sequence in the target nucleic acid, such that a complex is formed comprising the target nucleic acid and the circularizable probe;

(d) ligating the 3'"'"' and 5'"'"' ends of said circularizable probe with a ligating agent that joins nucleotide sequences such that a circular amplification probe is formed;

(e) washing the complex;

(f) amplifying said circular amplification probe by contacting said complex with a first extension primer that is complementary and hybridizable to a portion of the linker region of the circular amplification probe and a second extension primer that is substantially identical to a portion of the linker region of the circular amplification probe that does not overlap with the portion of the linker region to which the first extension probe is complementary, dNTPs, and a DNA polymerase having strand displacement activity, under conditions whereby the first extension primer is extended around the circle for multiple revolutions to form a single stranded DNA of repeating units complementary to the sequence of the circular probe, and multiple copies of the second extension primer hybridize to complementary regions of the single stranded DNA and are extended by the DNA polymerase to provide extension products, and whereby the extension products of the second extension primers displace downstream copies of the second extension primers and corresponding extension products to provide displaced single strands to which multiple copies of said first extension primer bind and are extended by the DNA polymerase;

(g) allowing said amplification to proceed until multiple copies of double stranded amplified DNA of varying lengths are produced; and

(h) detecting said amplified DNA, wherein detection thereof indicates the presence of the target nucleic acid in the clinical sample.

4. A method for in situ detection of a target nucleic acid in a sample comprising the steps of:

(a) preparing a tissue sample from the histological specimen to be analyzed for the presence of the target nucleic acid;

(b) washing said tissue sample;

(c) adding a circularizable amplification probe having 3'"'"' and 5'"'"' regions that are complementary to adjacent but noncontiguous sequences in the target nucleic acid, said 3'"'"' and 5'"'"' regions separated by a linker region that is neither complementary nor hybridizable to a nucleotide sequence in the target nucleic acid, such that a complex is formed comprising the target nucleic acid and the circularizable probe;

(d) ligating the 3'"'"' and 5'"'"' ends of said circularizable probe with a ligating agent that joins nucleotide sequences such that a circular amplification probe is formed;

(e) washing the complex;

(f) amplifying said circular amplification probe by contacting said complex with an extension primer that is complementary and hybridizable to a portion of the linker region of the circular amplification probe, dNTPs, and a DNA polymerase having strand displacement activity, under conditions whereby said extension primer is extended around the circle for multiple revolutions to form a single stranded DNA of repeating units complementary to the sequence of the circular probe; and

(g) detecting said single stranded DNA, wherein detection thereof indicates the presence of the target nucleic acid in the clinical sample.